Cargando…

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

AIMS: Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb‐oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once‐daily oral drug to treat sickle cell disease (SCD). This first‐in‐human study evaluated the safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hutchaleelaha, Athiwat, Patel, Mira, Washington, Carla, Siu, Vincent, Allen, Elizabeth, Oksenberg, Donna, Gretler, Daniel D., Mant, Timothy, Lehrer‐Graiwer, Josh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533444/ https://www.ncbi.nlm.nih.gov/pubmed/30743314 http://dx.doi.org/10.1111/bcp.13896

Ejemplares similares

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
por: Telfer, Paul, et al.
Publicado: (2018)

GBT440 Inhibits Sickling of Sickle Cell Trait Blood Under In Vitro Conditions Mimicking Strenuous Exercise
por: Dufu, Kobina, et al.
Publicado: (2016)

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin
por: Metcalf, Brian, et al.
Publicado: (2017)

GBT440 reverses sickling of sickled red blood cells under hypoxic conditions in vitro
por: Dufu, Kobina, et al.
Publicado: (2018)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Increased hemoglobin–oxygen affinity ameliorates bleomycin‐induced hypoxemia and pulmonary fibrosis
por: Geng, Xin, et al.
Publicado: (2016)

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease
por: Minniti, Caterina P., et al.
Publicado: (2021)

Rheological Impact of GBT1118 Cessation in a Sickle Mouse Model
por: Kanne, Celeste K., et al.
Publicado: (2021)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
por: Savic, Radojka M., et al.
Publicado: (2022)

Voxelotor: A Ray of Hope for Sickle Disease
por: AlDallal, Salma M
Publicado: (2020)

The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia
por: Al Balushi, Halima, et al.
Publicado: (2019)

Patient perception of voxelotor treatment benefit in sickle cell disease
por: Idowu, Modupe, et al.
Publicado: (2022)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
por: Barriteau, Christina M, et al.
Publicado: (2022)

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
por: Yenamandra, Avani, et al.
Publicado: (2020)

P1450: VOXELOTOR TREATMENT LEADS TO IMPROVED VIABILITY OF SICKLE ERYTHROCYTES
por: Konté, Kadère, et al.
Publicado: (2023)

Improvement of hemolytic anemia with GBT1118 is renoprotective in transgenic sickle mice
por: Ren, Guohui, et al.
Publicado: (2022)

Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe
por: Ferlis, Mica, et al.
Publicado: (2022)

Modeling the public health impact of voxelotor in the management of sickle cell disease in France
por: Galacteros, Frédéric, et al.
Publicado: (2023)

The GBT Project
por: Moreira, P, et al.
Publicado: (2009)

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action
por: Green, Michelle L., et al.
Publicado: (2022)

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
por: Glaros, Alexander K., et al.
Publicado: (2021)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

5610417 IN-VITRO REAL-TIME OBSERVATION OF MODERATE SICKLING KINETICS IN SICKLE ERYTHROCYTES TREATED BY VOXELOTOR UNDER MONOTONIC AND CYCLIC HYPOXIA
por: Qiang, Y.Q., et al.
Publicado: (2023)

lpGBT Status and Plans
por: Kulis, Szymon Krzysztof
Publicado: (2018)

GBT Project: Present & Future
por: RODRIGUES SIMOES MOREIRA, Paulo
Publicado: (2014)

lpGBT documentation: release
por: Moreira, Paulo, et al.
Publicado: (2022)

Integrating the GBT into standard networks
por: The ATLAS collaboration
Publicado: (2022)

More to voxelotor than meets the eye?
por: Bovino, Robert C., et al.
Publicado: (2022)

PB2516: ACTIGRAPHY IMPROVEMENT WITH VOXELOTOR (ACTIVE) STUDY: IMPACT OF VOXELOTOR ON PHYSICAL ACTIVITY, FATIGUE, AND SLEEP QUALITY
por: Shah, Nirmish, et al.
Publicado: (2023)

P-022: THERAPEUTIC EFFECTS OF GBT1118 ON SKELETAL MUSCLE ENERGETICS AND FUNCTION IN SICKLE CELL MICE
por: C., MICHEL, et al.
Publicado: (2022)

Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?
por: Tayyaba Rehan, Syeda, et al.
Publicado: (2022)

Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study
por: Brown, Clark, et al.
Publicado: (2023)

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2023)

P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, Biree, et al.
Publicado: (2023)

New slow-control FPGA IP for GBT based system and status update of the GBT-FPGA project
por: Mendez, Julian Maxime, et al.
Publicado: (2018)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

The LpGBT Project, Status and Overview
por: RODRIGUES SIMOES MOREIRA, Paulo
Publicado: (2016)

non-GBT links for data transmission
por: MILLER, Merritt Philip
Publicado: (2016)

The GBT-SerDes ASIC prototype
por: Moreira, P, et al.
Publicado: (2010)

The GBT-FPGA core: features and challenges
por: Barros Marin, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6slft7h3d9hmvhf7cmqo7nqpdp